Background Currently, the first choice for treatment of patients with ST-segment elevation myocardial infarction (STEMI) is percutaneous coronary intervention (PCI), and previous studies have found that cardiomyopeptidin can improve myocardial ischemia-reperfusion injury and have potential benefits for the clinical outcome of STEMI patients undergoing PCI.
Objective To investigate the myocardium protection effect of cardiomyopeptidin in patients with STEMI receiving PCI therapy.
Methods Consecutive patients who received PCI treatment in the department of cardiology, the First Medical Center, Chinese PLA General Hospital from July 2014 to June 2017 were recruited in the study. These patients were randomized to cardiomyopeptidin group (n=154) and control group (n=156). The enrolled patients received intravenous infusion 3 mg/(kg·d) of cardiomyopeptidin orplacebo (0.9% sodium chloride injection) during the PCI until 3 days after operation, respectively. The left ventricular ejection fraction (LVEF) was evaluated with Doppler echocardiography at 7 - 30 days after PCI. The 6-minute walk test was used to evaluate the patients’ exercise capacity at one month after PCI. And we also observed the change of B-type natriuretic peptide (BNP) before and after PCI.
Results Compared with control group, the LVEF increased significantly in cardiomyopeptidin group when patients were discharged from hospital (57.8% ± 12.8% vs 51.0% ± 12.1%, P＜0.001). There was a significant decrease of BNP level after operation in the cardiomyopeptidin group (MdIQR: 848 732, 940 pg/mL vs 1 1501 038, 1 245 pg/mL, P＜0.001). In addition, the distance of 6-minute walking test increased markedly in the cardiomyopeptidin group (773.7 ± 166.2 m vs 618.2 ± 186.3 m, P＜0.001).
Conclusion Cardiomyopeptidin can improve LVEF and exercise tolerance in STEMI patients treated with PCI, making it a potential adjuvant therapy for STEMI patients treated with PCI.
DownLoad: